Lipid lowering: statins and the future
نویسندگان
چکیده
منابع مشابه
Lipid lowering: statins and the future.
Cardiovascular disease (CVD) is the leading cause of death in developed and many developing countries. Between 1970 and 1992 there has been a slow decline in some areas, notably North America, Western Europe, Australia, and New Zealand. However, CVD mortality has recently increased in Eastern and Central Europe. A whole spectrum of therapeutic tools is available to manage CVD including thrombol...
متن کاملStatins: Newer Roles Including Lipid Lowering Therapy
Statins are most effective pharmacologically agents to decrease total plasma cholesterol level by competitive inhibition of HMG-Co A reductase. Apart from the well-known LDL and cholesterol lowering effect, statins have been postulated to exert other beneficial effects also called pleotropic or non-lipid effects. Better understanding of various pleotropic effects of statins has prompted a new s...
متن کاملstatins: newer roles including lipid lowering therapy
statins are most effective pharmacologically agents to decrease total plasma cholesterol level by competitive inhibition of hmg-co a reductase. apart from the well-known ldl and cholesterol lowering effect, statins have been postulated to exert other beneficial effects also called pleotropic or non-lipid effects. better understanding of various pleotropic effects of statins has prompted a new s...
متن کاملBenefits of statins beyond lipid lowering
Increasing evidence has accumulated suggesting that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or statins, have therapeutic ‘pleiotropic’ effects independent of cholesterol lowering. These include anti-inflammatory and antioxidative properties, improvement of endothelial function and increased nitric oxide bioavailability. In addition to elucidating underlying mech...
متن کاملStatins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins.
Cholesterol lowering involving different therapies improves the clinical outcome of patients. To define the underlying pathomechanism, we studied whether treatment with statins was associated with changes in blood thrombogenicity, endothelial dysfunction and soluble adhesion molecule levels. Fifty hypercholesterolemic patients were treated with pravastatin (40 mg/day, n=24) or simvastatin (20 m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Heart
سال: 2000
ISSN: 0007-0769
DOI: 10.1136/heart.84.suppl_1.i46